Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: Danon Disease Phase 1 RP-A501
Logo

American Heart Association

  133
  0

Final ID:

Discussant: Danon Disease Phase 1 RP-A501

  • Gillmore, Julian  ( UCL Centre for Amyloidosis , London , United Kingdom )
  • Taylor, Matthew  ( University of Colorado Health Sciences Center , Aurora , Colorado , United States )
  • Adler, Eric  ( Ucsd , La Jolla , California , United States )
    • Author Disclosures:
    Julian Gillmore: DO have relevant financial relationships ; Consultant:Alnylam, ATTRalus, AstraZeneca, Bridgebio, Lycia, Intellia, Pfizer:Active (exists now) | Matthew Taylor: DO NOT have relevant financial relationships | Eric Adler: DO have relevant financial relationships ; Employee:Lexeo Therapeutics:Active (exists now) ; Consultant:Kiniska Pharmaceuticals:Past (completed) ; Consultant:Abbott:Past (completed) ; Consultant:Abiomed:Past (completed) ; Ownership Interest:Papillion Therapeutics:Active (exists now) ; Other (please indicate in the box next to the company name):Solid Biosciences:Past (completed) ; Research Funding (PI or named investigator):Rocket Pharmaceuticals:Past (completed) ; Royalties/Patent Beneficiary:Rocket Pharmaceuticals:Active (exists now) ; Individual Stocks/Stock Options:Lexeo Therapeutics:Active (exists now) ; Royalties/Patent Beneficiary:Lexeo Therapeutics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Fontana Marianna, Maurer Mathew, Gillmore Julian, Bender Shaun, Aldinc Emre, Eraly Satish, Jay Patrick, Solomon Scott

Mavacamten Treatment in Patients with Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results from VALOR-HCM Trial

Desai Milind, Nissen Steven

More abstracts from these authors:
ATTR Genetic Screening and Subsequent Management in Underrepresented Populations-Bridging the Gap 10 minutes

Ruberg Frederick, Gillmore Julian

Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy

Greenberg Barry, Coggins Matthew, Schwartz Jonathan, Rossano Joseph, Taylor Matthew, Colan Steven, Adler Eric, Ricks David, Yarabe Paul, Battiprolu Pavan, Shah Guarav, Patel Kinnari

You have to be authorized to contact abstract author. Please, Login
Not Available